Latest News and Press Releases
Want to stay updated on the latest news?
-
ORLANDO, Fla., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted...
-
- Industry veteran to lead development of optimized programs for Iomab-B including initiatives targeted at patients, physicians and payors designed to support clinical development and...
-
- Members of Actinium’s executive and clinical development teams to participate in conference activities and extend the visibility of the Company’s Iomab-B drug candidate to the bone marrow transplant...
-
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
-
NEW YORK, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
-
NEW YORK, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
-
- Phase 1 trial will evaluate Actimab-M in treating patients with multiple myeloma who are unresponsive to currently available therapies - Clinical trial initiated at Texas Oncology - Baylor Charles...
-
- Dr. Berger’s presentation included in session on Immunotherapy and Bispecific Inhibitors in Acute Leukemia - Two day event will be attended by transplant physicians and hematologists...
-
Representatives from Actinium will attend to promote awareness among attending physicians and health professionals on Iomab-B and the SIERRA trial NEW YORK, Jan. 20, 2017 (GLOBE NEWSWIRE) --...
-
Dr. Berger brings 20 years of drug development experience highlighted by the FDA approvals of Mylotarg® for acute myeloid leukemia, the only drug approved in AML in several decades, and Tykerb® for...